TheBioTechReview

Industry Radar

Exploring the latest in Industry Radar.

Beyond the $2B Deal: How Novartis' Acquisition of Inavolisib Signals a Strategic Shift in Precision Oncology
Industry Radar

Beyond the $2B Deal: How Novartis' Acquisition of Inavolisib Signals a Strategic Shift in Precision Oncology

Beyond Genetics: How Rhythm Pharma's FDA Win Redefines the Obesity Market and Brain-Body Pathways
Industry Radar

Beyond Genetics: How Rhythm Pharma's FDA Win Redefines the Obesity Market and Brain-Body Pathways

Beyond the Dose: How Novo Nordisk's Priority Voucher Strategy Reveals Pharma's New Playbook
Industry Radar

Beyond the Dose: How Novo Nordisk's Priority Voucher Strategy Reveals Pharma's New Playbook

Beyond the Mutation: How Pfizer's Talzenna Data Redefines Prostate Cancer Treatment Economics
Industry Radar

Beyond the Mutation: How Pfizer's Talzenna Data Redefines Prostate Cancer Treatment Economics

Beyond the 20% Surge: How Apogee's Infrequent-Dosing Eczema Drug Could Reshape the Biopharma Business Model
Industry Radar

Beyond the 20% Surge: How Apogee's Infrequent-Dosing Eczema Drug Could Reshape the Biopharma Business Model

Beyond the Headline: AstraZeneca's Shanghai Cell Therapy Bet and China's Biotech Power Play
Industry Radar

Beyond the Headline: AstraZeneca's Shanghai Cell Therapy Bet and China's Biotech Power Play